FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 599 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Neoadjuvant ICI Without Chemotherapy Demonstrates Potential Efficacy in Patients with Early-Stage... November 21, 2024 Microplastics Can Be Detected In Human Organ Tissue August 20, 2020 I Received the COVID-19 Vaccine – Now What? February 8, 2021 Adding Atezolizumab to Chemotherapy Does Not Improve Outcomes in Patients Who... June 4, 2024 Load more HOT NEWS Clinical Trial Results Support Uninterrupted Use of Imatinib for Some Gastrointestinal... Determination of the Incidence of Driver Mutations in Patients with NSCLC... Osimertinib Shows Promising Activity in Previously Untreated Patients with Metastatic NSCLC... Adding Autologous Stem-Cell Transplantation to Triplet Treatment, Followed by Lenalidomide Maintenance...
